Stifel Reiterates Buy Rating on Evolus (EOLS)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Stifel Reiterates Buy Rating on Evolus (EOLS)

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

January 21, 2025 8:00 AM EST

Expects U.S. Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

Provides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability1

Preliminary Unaudited Net Revenue of $79.0 Million for the Fourth Quarter 2024, Representing 30% Growth Over the Prior Year Preliminary Unaudited Net Revenue of $266.3 Million for the Full-Year 2024, Representing 32% Growth Over the Prior Year and at the Top of the Companys Guidance Expects U.S. Food and Drug Administration (FDA) Approval Within 90 Days for Evolysse Form and Evolysse Smooth Injectable... More

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 17, 2025 4:05 PM EST

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the companys common stock to 6 newly hired... More